Zidovudine vs Abacavir — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Zidovudine

Brand: RETROVIR

First FDA approval: 2005-09-19

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Abacavir

Brand: Abacavir

First FDA approval: 1999-01-28

Lowest NADACAcquisition cost floor across all NDCs

$0.150Per unit

$0.652Per unit

Average NADACAcross all dosage forms and strengths

$0.291Up to $0.432

$0.652Up to $0.652

Generic manufacturersActive ANDA holders — FDA Orange Book

47 total ANDAs filed

57 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$250683Full year

$4.2MFull year

Part D claims (CY24)Total fills, all strengths

4K706 beneficiaries

23K4K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$66Per claim, all NDCs

$180Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes4 manufacturers

Yes5 manufacturers